chr2-47482945-C-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000251.3(MSH2):c.2801C>T(p.Thr934Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000323 in 1,610,486 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.2801C>T | p.Thr934Met | missense_variant | 16/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.2801C>T | p.Thr934Met | missense_variant | 16/16 | 1 | NM_000251.3 | ENSP00000233146.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152114Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000566 AC: 14AN: 247562Hom.: 0 AF XY: 0.0000596 AC XY: 8AN XY: 134218
GnomAD4 exome AF: 0.0000350 AC: 51AN: 1458372Hom.: 0 Cov.: 31 AF XY: 0.0000441 AC XY: 32AN XY: 725330
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152114Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74294
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 28, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 29, 2023 | This missense variant replaces threonine with methionine at codon 934 of the MSH2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer, ovarian cancer, gastrointestinal stromal tumor and unspecified cancer (PMID: 19117025, 26898890, 27498913, 29596542, 31391288, 31569399) with some tumors exhibiting proficient mismatch repair abilities (PMID: 29596542, 31391288). This variant has been reported to occur in affected individuals together with another disease-causing variant in the MLH1 or MSH2 gene that could explain the observed phenotype (ClinVar variation ID: 127641). This variant has been identified in 14/247562 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | May 05, 2021 | - - |
not specified Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 25, 2022 | Variant summary: MSH2 c.2801C>T (p.Thr934Met) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 5.7e-05 in 247562 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in MSH2 causing Hereditary Nonpolyposis Colorectal Cancer (5.7e-05 vs 0.00057), allowing no conclusion about variant significance. c.2801C>T has been reported in the literature as a VUS in settings of multigene panel testing in individuals affected with HBOC, colorectal cancer in addition to an individual referred for genetic testing (example, Caminsky_2016, Hampel_2018, Mu_2016, South_2009, Wu_2019). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer/Lynch syndrome. At-least two co-occurrences with other pathogenic variant(s) have been reported in the UMD database (MLH1 c.2252_2253del, p.Lys751SerfsX3; MSH2 c.1661+1G>T), providing supporting evidence for a benign role. One of these individuals who harbors the co-occuring causal variant in MLH1 is reported as having mismatch repair (MMR) function in tumor cells as MLH1 negative and MSH2 positive which is consistent with the observed variant spectrum. To our knowledge, no other experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=4; VUS, n=2). Based on the evidence outlined above, the variant was classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 04, 2021 | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29596542, 31391288, 26898890, 27720647, 19117025, 27498913, 31569399) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 30, 2024 | The MSH2 c.2801C>T (p.Thr934Met) variant has been reported in the published literature in individuals affected with breast cancer and ovarian cancer (PMIDs: 19117025 (2009), 26898890 (2016), 31569399 (2019)), as well as in individuals referred for multigene hereditary cancer panel testing (PMID: 27720647 (2016)). It has also been reported in individuals with breast cancer as well as in unaffected controls in a breast cancer association study (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/MSH2)). The frequency of this variant in the general population, 0.0001 (3/30122 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Carcinoma of colon Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MSH2 p.Thr934Met variant was identified in 2 of 728 proband chromosomes (frequency: 0.003) from individuals or families with Lynch syndrome and ovarian cancer (Caminsky 2016, South 2009). The variant was also identified in the following databases: dbSNP (ID: rs587779969 as “With Uncertain significance allele”), ClinVar (1x as likely benign by Invitae and 3x uncertain significance by GeneDx, Ambry Genetics, and Color Genomics), UMD-LSDB (5x as neutral), Insight Colon Cancer Gene Variant Database, and Insight Hereditary Tumors Database. The variant was not identified in the COGR, Cosmic, MutDB, Zhejiang University Database, or Mismatch Repair Genes Variant Database. The variant was identified in control databases in 14 of 243082 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 2 of 14858 chromosomes (freq: 0.0001), Latino in 1 of 33348 chromosomes (freq: 0.00003), European (Non-Finnish) in 7 of 110080 chromosomes (freq: 0.00006), Finnish in 1 of 22236 chromosomes (freq: 0.00005), and South Asian in 3 of 30260 chromosomes (freq: 0.0001); it was not observed in the Other, Ashkenazi Jewish, or East Asian populations. The variant was identified in our lab with a co-occurring pathogenic PMS2 variant (p.Gln719Argfs*6) increasing the likelihood that the p.Thr934Met variant does not have clinical significance. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. The p.Thr934 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Mar 05, 2024 | This missense variant replaces threonine with methionine at codon 934 of the MSH2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer, ovarian cancer, gastrointestinal stromal tumor and unspecified cancer (PMID: 19117025, 26898890, 27498913, 29596542, 31391288, 31569399) with some tumors exhibiting proficient mismatch repair abilities (PMID: 29596542, 31391288). This variant has been reported to occur in affected individuals together with another disease-causing variant in the MLH1 or MSH2 gene that could explain the observed phenotype (ClinVar variation ID: 127641). This variant has been identified in 14/247562 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Lynch syndrome 1 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at